Clinical Trial Search Results

Click on the name (title) to see the trial details in the LRG database. You will also have the opportunity to access trial site data later. Trials are sorted so that trials that are only for GIST appear first. Trials are also sorted so that trials in later phases sort higher on the list. The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database.

15 trials found
A Study of Olverembatinib in SDH-deficient GIST. (POLARIS-3)
Phase:   3
  
Drug Category:  SDH-directed
Conditions: Gastrointestinal Stromal Tumor
Treatment Phase: Gleevec-resistant
Status:  Not yet recruiting
Site
City
State
Country
Sun-Yat Sen University Cancer Center Guangzhou Guandong China


Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI)
Phase:   2
  
Drug Category:  SDH-directed
Conditions: Gastrointestinal Stromal Tumor
Treatment Phase: First-line
Status:  Completed
Site
City
State
Country
Institut Bergonie Bordeaux Gironde France
Centre Léon Bérard Lyon Rhone France
Istituto Nazionale Dei Tumori Milan Italy
Universita Campus Bio-Medico di Roma Rome Italy
Hospital Universitario de Canarias Tenerife Spain
Hospital Vall d'Hebron Barcelona Spain
Hospital Santa Creu i Sant Pau Barcelona Spain
University Hospital La Paz Madrid Spain
hospital Universitario Miguel Servet Zaragosa Spain
Instituto di Candiolo - IRCSS Torino Italy
Hospital de Cruces Barakaldo Spain
Hospital Universitario Gregorio Maranon Madrid Spain
Hospital Universitario Virgen de la Macarena Sevilla Spain
Instituto Valencia de Oncologia Valencia Spain
Hospital Virgen del Rocio Sevilla Spain
Institut Gustave Roussy Villejuif Val de Narne France
Site name unknown Napoli 80131 Napoli Italy
Site name unknown Napoli 80131 Napoli Italy


Temozolomide in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors
Phase:   2
  
Drug Category:  SDH-directed
Conditions: Gastrointestinal Stromal Tumor
Treatment Phase: First-line
Status:  Completed
Site
City
State
Country


Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor
Phase:   2
  
Drug Category:  SDH-directed
Conditions: Gastrointestinal Stromal Tumor
Treatment Phase: Gleevec-resistant
Status:  Active, not recruiting
Site
City
State
Country
Moores Cancer Center/UCSD Medical center La Jolla CA USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Dana Farber Cancer Institute Boston MA USA
Knight Cancer Institute at Oregon Health Sciences University (OHSU) Portland OR USA
Fox Chase Cancer Center Philadelphia PA USA


Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Phase:   2
  
Drug Category:  SDH-directed
Conditions: Gastrointestinal Stromal Tumor
Treatment Phase: Gleevec-resistant
Status:  Recruiting
Site
City
State
Country
Cedars-Sinai Outpatient Cancer Center Los Angeles CA USA
University of Iowa Hospitals and Clinics Iowa City IA USA
University of Michigan Ann Arbor MI USA
Washington University School of Medicine St. Louis MO USA
Mount Sinai School of Medicine New York NY USA
Abramson Cancer Center - University of Pennsylvania Philadelphia PA USA
Vanderbilt-Ingram Cancer Center Nashville TN USA
MD Anderson Cancer Center Houston TX USA
Peking University First Hospital-Urology Beijing Beijing China
Prince of Wales Hospital Randwick New South Wales Australia
Royal Melbourne Hospital Parkville Victoria Australia
Tom Baker Cancer Center Calgary AB Canada
Princess Margaret Hospital Toronto ON Canada
CHRU Strasbourg - Hôpital Hautepierre Strasbourg France
Institut Paoli-Calmette Marseille Bouches du Rhone France
Institut Gustave Roussy Villejuif Val de Narne France
Hopital Edouard Herriot Lyon France
University of Freiburg - Tumor Biology Center Freiburg Germany
Charite Comprehensive Cancer Center (CCCC) Berlin Germany
Instituto Europeo di Oncologia Milano Italy
Hokkaido University Hospital Sapporo Hokkaido Japan
Universitair Medisch Centrum Utrecht Netherlands
National Cancer Center Singapore Singapore
Hospital 12 octobre Madrid Spain
Hospital Vall d'Hebron Barcelona Spain
Dept. of Oncology, Skane University Lund Sweden
Dept. of Oncology, Academic Hospital Uppsala Sweden
Beatson West of Scotland Cancer Centre Glasgow UK
Johns Hopkins Sidney Kimmel Comp Cancer Center Baltimore MD USA
Sheba Medical Center Rahat Israel
Azianda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento Verona Italy
National Cancer Center Hospital Chuo-ku Tokyo Japan
Karolinska University Hospital Solna Sweden
Dept. of Oncology, Sahlgrenska University Hospital Gothenburg Sweden
Cambridge University Hospitals Cambridge UK
Massachusetts General Hospital Boston MA USA
Renji Hospital Shanghai Jiao Tong University School of Medicine Shanghai Shanghai China
West China Hospital of Sichuan University Cheng Du Sichaun China
Rigshospitalet-Department of Endocrinology Copenhagen Hovedstaden Denmark
Odense Universitetshospital Odense Syddanmark Denmark
Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre Paris France
Hopitaux Universitaires Paris Centre-Hopital Cochin Paris France
Klinikum der Ludwig-Maximilians-Universitaet Muenchen Munchen Bayern Germany
Comprehensive Cancer Center Mainfranken Wurzburg Bayern Germany
Semmelweis University-Belgyógyászati és Onkológiai Klinika Hematológia Osztály Budapest Hungary
University of Naples Federico II Naples Campania Italy
Ospedale San Raffaele-Oncologia Medica Milano Lombardia Italy
Azienda Ospedaliera Spedali Civili di Brescia-Oncology Brescia Italy
Yokohama City University Hospital Yokohama Kanagawa Japan
Kochi Medical School Hospital Nankoku Kochi Japan
Kyoto University Hospital Kyoto Japan
Tokyo Women's Medical University Adachi Medical Center Tokyo Japan
Hospital Universitario Central de Asturias-Medical Oncology Oviedo Asturias Spain
MD Anderson Cancer Center-Oncology Madrid Madrid Spain
Ege University Medicine of Faculty Bornova Izmir Turkey
Hacettepe Universitesi-oncology hospital Ankara Turkey
Ankara Bilkent Şehir Hastanesi. Ankara Turkey
Istanbul Universitesi Cerrahpasa-Medical Oncology Istanbul Turkey
Royal Free Hospital London England UK
Hammersmith Hospital-Medical Oncology London UK
National Cancer Institute Bethesda MD USA
Tel-Aviv Sourasky Medical Center Tel Aviv Israel
Sun Yat-sen University Cancer Center Guangzhou Guandong China
Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology Düsseldorf Nordheim-Westfalen Germany
Rigshospitalet Copenhagen Hovedstaden Denmark


M6620 (VX-970) in Selected Solid Tumors
Phase:   2
  
Drug Category:  SDH-directed
Conditions: Gastrointestinal Stromal Tumor
Treatment Phase: First-line
Status:  Completed
Site
City
State
Country
Dana Farber Cancer Institute Boston MA USA
Beth Israel Deaconess Medical Center Boston MA USA
Massachusetts General Hospital Boston MA USA
Children's Hospital Boston MA USA


A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer
Phase:   2
  
Drug Category:  SDH-directed
Conditions: SDH- GIST
Treatment Phase: First-line
Status:  Completed
Site
City
State
Country
National Cancer Institute Bethesda MD USA


Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
Phase:   2
  
Drug Category:  SDH-directed
Conditions: Sarcoma
Treatment Phase: Gleevec-resistant
Status:  Active, not recruiting
Site
City
State
Country
Dana Farber Cancer Institute Boston MA USA
National Cancer Institute Bethesda MD USA
City of Hope Duarte CA USA
Memorial Sloan Kettering New York NY USA
Washington University School of Medicine St. Louis MO USA
University of Pittsburgh Cancer Institute Pittsburgh PA USA
University of Colorado Aurora CO USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
University of Michigan Ann Arbor MI USA
Ohio State University Comprehensive Cancer Center Columbus OH USA
Vanderbilt-Ingram Cancer Center Nashville TN USA
City of Hope Irvine Lennar Irvine CA USA
Robert Lurie Comp. Cancer Center Northwestern University Hospital Chicago IL USA
MD Anderson Cancer Center Houston TX USA


Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Phase:   1
  
Drug Category:  SDH-directed
Conditions: Solid Tumors
Treatment Phase: Gleevec-resistant
Status:  Active, not recruiting
Site
City
State
Country
MD Anderson Cancer Center Houston TX USA
University of Pennsylvania Philadelphia PA USA
Memorial Sloan Kettering New York NY USA
UCSF Helen Diller Family Comprehensive Cancer Center San Francisco CA USA
Stanford University Medical Center Palo Alto CA USA
Florida Cancer Specialists Sarasota FL USA
Tennessee Oncology Nashville TN USA
Emory Winship Cancer Institute Atlanta GA USA
Dana Farber Cancer Institute Boston MA USA
Beth Israel Deaconess Medical Center Boston MA USA
Massachusetts General Hospital Boston MA USA
Columbia University - Herbert Irving Cancer Center New York NY USA
National Cancer Institute Bethesda MD USA


A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Phase:   1
  
Drug Category:  SDH-directed
Conditions: Solid Tumors
Treatment Phase: Gleevec-resistant
Status:  Recruiting
Site
City
State
Country
Sun-Yat Sen University Cancer Center Guangzhou Guandong China
Guangdong General Hospital Guangzhou Guangdong China
Union Hospital Medical College Huazhong University of Science and Technology Wuhan Hubei China
Chinese PLA General Hospital Beijing China
Fudan University Shanghai Cancer Center Shanghai China
Henan cancer hospital Zhengzhou Henan China


Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Phase:   1
  
Drug Category:  SDH-directed
Conditions: Gastrointestinal Stromal Tumor
Treatment Phase: Gleevec-resistant
Status:  Recruiting
Site
City
State
Country
HonorHealth Virginia Piper Cancer Center Scottsdale AZ USA
City of Hope Duarte CA USA
Sarcoma Oncology Center Santa Monica CA USA
University of Colorado Aurora CO USA
Emory Winship Cancer Institute Atlanta GA USA
University of Chicago Chicago IL USA
University of Michigan Ann Arbor MI USA
Cleveland Clinic Taussig Cancer Center Cleveland OH USA
Abramson Cancer Center - University of Pennsylvania Philadelphia PA USA
MD Anderson Cancer Center Houston TX USA
Inova Health System Fairfax VA USA
Memorial Sloan Kettering New York NY USA
START Midwest Michigan, PC Grand Rapids MI USA
Virginia Cancer Specialists Fairfax VA USA
Valkyrie Clinical Trials INC Los Angeles CA USA
Knight Cancer Institute at Oregon Health Sciences University (OHSU) Portland OR USA
Moores Cancer Center/UCSD Medical center La Jolla CA USA
National Cancer Institute Bethesda MD USA
Oregon Health & Science University Portland OR USA
Vanderbilt-Ingram Cancer Center Nashville TN USA


Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Phase:   1/2
  
Drug Category:  SDH-directed
Conditions: Solid Tumors
Treatment Phase: Gleevec-resistant
Status:  Terminated
Site
City
State
Country
South Texas Accelerated Research Therapeutics (START) San Antonio TX USA
UAB Comprehensive Cancer Center Birmingham AL USA
Emory Winship Cancer Institute Atlanta GA USA
University of Iowa Hospitals and Clinics Iowa City IA USA
Massachusetts General Hospital Boston MA USA
Columbia University - Herbert Irving Cancer Center New York NY USA
MD Anderson Cancer Center Houston TX USA
Huntsman Cancer Institute Salt Lake City UT USA
Carbone Cancer Center, University of Wisconsin Madison WI USA


Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
Phase:   2
  
Drug Category:  SDH-directed
Conditions: Solid Tumors
Treatment Phase: Gleevec-resistant
Status:  Active, not recruiting
Site
City
State
Country
H. Lee Moffit Cancer Center Tampa FL USA
Warren Grant Magnuson Clinical Center Bethesda MD USA
Dana Farber Cancer Institute Boston MA USA
Columbia University - Herbert Irving Cancer Center New York NY USA
Ohio State University Comprehensive Cancer Center Columbus OH USA
University of Pittsburgh Cancer Institute Pittsburgh PA USA
MD Anderson Cancer Center Houston TX USA
Moffitt Cancer Center-International Plaza Tampa FL USA
University of Kentucky/Markey Cancer Center Lexington KY USA
UAB Comprehensive Cancer Center Birmingham AL USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Miami Cancer Institute at Baptist Health Miami FL USA
Robert Lurie Comp. Cancer Center Northwestern University Hospital Chicago IL USA
University of Kansas Cancer Center Westwood KS USA
Warren Grant Magnuson Clinical Center Bethesda MD USA
New York University New York NY USA
University of North Carolina (UNC) Chapel Hill NC USA


Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
Phase:   2
  
Drug Category:  SDH-directed
Conditions: Solid Tumors
Treatment Phase: Gleevec-resistant
Status:  Terminated
Site
City
State
Country
Eastchester Center for Cancer Bronx NY USA


A Trial of PT2977 Tablets In Patients With Advanced Solid Tumors
Phase:   1
  
Drug Category:  SDH-directed
Conditions: Solid Tumors
Treatment Phase: Gleevec-resistant
Status:  Active, not recruiting
Site
City
State
Country
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Dana Farber Cancer Institute Boston MA USA
Beth Israel Deaconess Medical Center Boston MA USA
Massachusetts General Hospital Boston MA USA
Wake Forrest Winston-Salem NC USA
Tennessee Oncology Nashville TN USA
South Texas Accelerated Research Therapeutics (START) San Antonio TX USA


15 trials found